Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2016

View Archived Issues

Phase I safety and pharmacokinetic results for BHV-0223

Orphan drug designation granted for RE-024 in Europe for the treatment of PKAN

European orphan drug designation for EYS-606 in refractory noninfectious uveitis

Data presented for phase II RADIANCE study of ozanimod

FDA approves Pfizer's Xeljanz XR extended-release tablets

Initiation of phase II study of fostamatinib in autoimmune hemolytic anemia

Alkermes announces positive topline results for 2-month dosing option of Aristada

FDA grants orphan drug designation to ZYN-002 for Fragile X syndrome

Roche discloses BACE1 inhibitors

Narcan now available in U.S. for the treatment of opioid overdose

Redx Pharma patents antibacterial compounds

Pfizer patent reports JAK inhibitors

University of British Columbia introduces pyruvate kinase inhibitors

PI3K and mTOR inhibitors described in Shandong Huiruidi Biotechnology patent

Interim phase III analysis shows improved pain scores in ER patients treated with ARX-04

Seattle Genetics initiates phase I trial of SGN-CD19B

NephroGenex pauses Pyridorin clinical program, restructures

Novartis seeks Japanese approval of artemether/lumefantrine

Phase I safety and PK data presented for BMS-986120

Teva to begin strategic corporate identity program to build global brand

UCB terminates epratuzumab agreement with Immunomedics

Takeda's combination packs for H. pylori eradication approved in Japan

EMA grants orphan drug designation to TNT-009 for autoimmune hemolytic anemia

Peregrine stops phase III bavituximab study in NSCLC following interim analysis

FDA places pivotal study of CR-845 for postoperative pain on protocol clinical hold

OSE Pharma and Effimune to merge

Luminex to validate GenArraytion's Zika virus assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...